Tom has more than 15 years commercial experience in biopharmaceutical development and bioproduction. He has previously held R&D and commercially-focused roles at both Novozymes Biopharma (now Albumedix) and Lonza in the UK.
At OXGENE, Tom is responsible for technology development activities, spanning the breadth of services and products offered. His research interests include gene editing, synthetic biology and cellular engineering. Tom holds a BSc and Ph.D in Molecular Biology from the University of Nottingham.